GlaxoSmithKline is looking to form long-term partnerships with top university researchers to more effectively develop new drugs. GSK wants to work closely with these "superstar researchers" from the initial research stages all the way through to drug launch. This will allow GSK to benefit from the universities' knowledge while providing funding for the researchers that will be paid back if an successful drug results. GSK has already signed an agreement with Professor Mark Pepys from University College London to develop a treatment for a rare heart condition.